Tempus AI’s (TEM) Buy Rating Reiterated at Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of Tempus AI (NASDAQ:TEM) in a research note released on Monday morning, Marketbeat reports. Needham & Company LLC currently has a $75.00 price objective on the stock.

Other equities analysts also recently issued research reports about the stock. Jefferies Financial Group began coverage on shares of Tempus AI in a report on Monday, April 13th. They set an “underperform” rating and a $35.00 price objective on the stock. Wolfe Research started coverage on shares of Tempus AI in a research report on Tuesday, June 2nd. They set a “peer perform” rating on the stock. TD Cowen reissued a “buy” rating on shares of Tempus AI in a research report on Wednesday, July 15th. BTIG Research restated a “buy” rating and set a $80.00 price target on shares of Tempus AI in a research note on Monday, June 1st. Finally, HC Wainwright decreased their price target on shares of Tempus AI from $95.00 to $64.00 and set a “buy” rating for the company in a report on Monday, May 11th. Nine investment analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $68.92.

Tempus AI Stock Down 4.1%

Tempus AI stock opened at $46.96 on Monday. Tempus AI has a 1-year low of $41.73 and a 1-year high of $104.32. The business has a fifty day moving average price of $51.66 and a 200-day moving average price of $53.76. The company has a debt-to-equity ratio of 2.96, a current ratio of 3.31 and a quick ratio of 3.15. The stock has a market capitalization of $8.43 billion, a price-to-earnings ratio of -27.30 and a beta of 3.46.

Tempus AI (NASDAQ:TEM) last announced its earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.08. The company had revenue of $348.12 million for the quarter, compared to analyst estimates of $345.44 million. Tempus AI had a negative return on equity of 53.83% and a negative net margin of 22.20%.The firm’s quarterly revenue was up 36.1% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.24) EPS. Equities research analysts forecast that Tempus AI will post -1.35 EPS for the current fiscal year.

Insider Activity

In related news, Director Jennifer A. Doudna sold 2,673 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $55.00, for a total value of $147,015.00. Following the sale, the director owned 25,942 shares in the company, valued at $1,426,810. This represents a 9.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Eric P. Lefkofsky sold 166,250 shares of the stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $57.48, for a total transaction of $9,556,050.00. Following the completion of the transaction, the chief executive officer owned 8,775,283 shares in the company, valued at approximately $504,403,266.84. This trade represents a 1.86% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 616,043 shares of company stock valued at $31,748,593. 24.26% of the stock is owned by insiders.

Institutional Investors Weigh In On Tempus AI

Several hedge funds have recently bought and sold shares of TEM. Aberdeen Group plc lifted its holdings in Tempus AI by 64.2% during the fourth quarter. Aberdeen Group plc now owns 263,004 shares of the company’s stock valued at $15,530,000 after purchasing an additional 102,878 shares in the last quarter. Pictet Asset Management Holding SA increased its stake in shares of Tempus AI by 291.3% during the fourth quarter. Pictet Asset Management Holding SA now owns 48,488 shares of the company’s stock worth $2,948,000 after purchasing an additional 36,096 shares in the last quarter. Bogart Wealth LLC increased its stake in shares of Tempus AI by 365,087.5% during the fourth quarter. Bogart Wealth LLC now owns 58,430 shares of the company’s stock worth $3,450,000 after purchasing an additional 58,414 shares in the last quarter. Alethea Capital Management LLC acquired a new position in shares of Tempus AI during the 4th quarter worth about $1,863,000. Finally, Sumitomo Mitsui Trust Group Inc. raised its position in shares of Tempus AI by 1.2% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,504,823 shares of the company’s stock worth $206,960,000 after purchasing an additional 41,728 shares during the last quarter. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Trending Headlines about Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Tempus announced a national launch of OneOme pharmacogenomics testing, expanding its precision-medicine offerings and potentially improving patient safety and future revenue growth. Tempus Announces National Launch of OneOme Pharmacogenomics Testing, Advancing Patient Safety and Precision Medicine
• Positive Sentiment: Needham & Company reaffirmed a Buy rating on Tempus AI, signaling continued analyst confidence despite recent weakness. Needham & Company LLC Reaffirms Buy Rating for Tempus AI (NASDAQ:TEM)
• Neutral Sentiment: Analyst commentary on Tempus AI and other healthcare names offered additional context, but did not appear to materially change the investment thesis. Analysts Offer Insights on Healthcare Companies: Tempus AI, Inc. Class A (TEM) and 4D Molecular Therapeutics (FDMT)
• Negative Sentiment: Investor focus on Tempus’ large Personalis acquisition may be weighing on the stock, as the deal is expensive and could pressure margins or increase leverage before synergies are realized. Tempus AI (TEM) On Its Personalis Deal And Whether The Bull Case Is Priced In

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.